Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), Bloomberg reports.
According to Bloomberg, Mylan chairman Robert Coury has said in private conversation that his company’s management is considering improving its latest offer to Perrigo shareholders in order to reduce their risk yet further.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Coury is also reported as having told investors that he is determined to repel Teva’s bid…. [READ MORE]
Published by Globes [online], Israel business news – www.globes-online.com
READ MORE :
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) had an opportunity to acquire US pharmaceuticals company Perrigo Company (NYSE:PRGO; TASE:PRGO) a few months ago, and said it was not interested, sources More…
Three Way Takeover Battle: Mylan Chairman Tells Investors He Would Consider Buying Teva
Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd More…
Teva Takeover Supporter Paulson Raises Mylan Stake
John Paulson‘s hedge fund has increased its holdings in Mylan NV to 4.5%. The fund, which supports Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA; TASE: TEVA) takeover bid for Mylan, bought More…
Benny Landa: Teva Would Be Wrong to Buy Mylan
Benny Landa feels confused. The successful entrepreneur, one of the fathers of Israel’s digital printing equipment industry, does not quite understand why Israel’s Teva Pharmaceutical Industries Ltd. More…
Teva Sends Letter to Mylan Board: Shareholders Won’t Benefit From Mud Slinging
Mylan is using a bid for Perrigo to avoid a hostile takeover by Teva. Given sparkly valuations, it may be safer to be a seller than a buyer. April 29, 2015: Teva Pharmaceutical Industries Ltd. (NYSE and TASE: More…
“Even at $100 Per Share Teva’s Mylan Bid Worthwhile”
“Mylan Laboratories is a good acquisition target for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), and in my opinion, Teva’s shareholders will welcome it, but it also depends More…
Tamir Capital Soars After Court Ruling Against Teva
Shares in Tamir Capital are soaring on lively volumes, following a Tel Aviv District Court ruling that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) infringed the terms of a license from Proneuron More…
[Full Announcement] Mylan Board Unanimously Rejects Teva Bid: Low-Quality, High-Risk, Poor Record
Board concludes that approach grossly undervalues Mylan, includes Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of delivering shareholder value Proposed combination More…
Teva Undeterred by Mylan Rejection
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is undeterred by the rejection of its bid for Mylan N.V. (Nasdaq: MYL). Teva president and CEO Erez Vigodman said, “While we are disappointed that More…
